Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics

Drug Profile

Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics

Alternative Names: Aspirin derivative - Antibe Therapeutics; ATB 340; ATB-282; ATB-284; ATB-352; ATB-427; ATB-428; ATB-429

Latest Information Update: 07 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antibe Therapeutics
  • Class Analgesics; Anti-inflammatories; Anticoagulants; Sulfides
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute pain; Blood coagulation disorders
  • No development reported Inflammatory bowel diseases; Irritable bowel syndrome

Most Recent Events

  • 03 Jun 2019 Antibe Therapeutics plans to pursue a Fast Track designation with the FDA for ATB 352
  • 26 Feb 2018 Hydrogen sulfide based ATB 352 is still in preclinical development for Acute pain in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute pain in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top